The needle free injection market is projected to reach USD 25,057.4 million during the forecast period. Historically, humans have been provided medications by needles and injections. However, a novel idea known as needle free injection technology (NFIT) has recently entered the market, encompassing a diverse array of drug delivery devices. Through the skin, drugs are given by shock waves, gas pressure, or electrophoresis. This technique or force drives the medication through the skin without the use of a hypodermic needle.
The increasing number of diabetes cases worldwide has created a demand for self-injection systems, which are easily met by needle free injection systems; consequently, the market's expansion is being fueled by the growing demand for self-medication. Additionally, increased chronic illness prevalence and an increase in the utilization of injectable medications for therapy are boosting demand for needle free injection systems.
Injectable drug delivery systems have a number of advantages over oral drug delivery systems, including a speedier onset of action and maximum bioavailability, which makes them ideal for usage in emergency situations to provide immediate relief. Additionally, it is painless during administration, and needle-free injection devices distribute the medications more evenly throughout the dermis.
Additionally, needle-free injection devices help to eliminate infection risk. Due to the advantages of needle free injection systems over conventional needle systems, the market for needle free injection systems is quickly rising.
By product type, the needle free injection market has been segmented into prefilled and fillable needle free injectors. By technology, the needle free injection market is segmented into laser-powered, spring-based, and jet-based. By usability, the market is segmented into disposable and reusable needle free injectors.
By medication type, the needle free injection market is segmented into projectile/depot-based, powder-based, and liquid-based needle free injectors. By site of delivery, intradermal, intramuscular, and subcutaneous are segments in the market. Oncology, vaccination, insulin delivery, and others are major market applications. Prime end-users include ambulatory surgical centers, homecare settings, hospitals and clinics, and others.
The segments and sub-segments covered in the report are analyzed under four major regions –Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. For the scope of research, the standard definition of the product/ service “needle free injection” is included in the report. The report discusses and interprets the current and future opportunities of the industry delivering an unbiased growth assessment.
CROSSJECT, Medical International Technology, Inc., National Medical Products Inc., INJEX Pharma GmBH, PenJet Corporation, Valeritas Holdings, Inc., Antares Pharma Inc., D'Antonio Consultants International, Inc., MIKA MEDICAL CO., PharmaJet, Inc., Endo Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., and European Pharma Group are prominent players in the needle free injection market.
The report offers comprehensive profiles on these market players and assesses their current standing in the needle free injection market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, M&A activities, and latest R&D initiatives are outlined in the report.
Market Research Future (MRFR) uses a combination of primary and secondary research to compile market reports. Primary data is accumulated from interviewing industry stalwarts and secondary research is collated by studying white papers and annual reports of leading players. Our analysts use top-down and bottom-up approaches to validate the findings of the report. The report comprises news, current trends, and future prospects related to the market, all of which can provide a thorough understanding of the market to clients. Industry leaders can make accurate business decisions based on our insights.
February 2022: PharmaJet, a biotech business that pioneered the needle-free injection of medicines and biologics, stated that its partner, Technovalia, has released interim safety data from their needle-free SARS-CoV2 DNA vaccine phase 1 trial. COVIGEN's interim safety data indicate that their DNA COVID-19 vaccine candidate is well tolerated and poses no safety concerns.
February 2022: DIOSynVax, a spin-out business from the University of Cambridge, has been awarded USD 42 million to develop a vaccine candidate that could protect against a variety of coronaviruses, including future Covid-19 variations, and aid in the fight against pandemics. The vaccination is administered via 'injection' without the use of needles.
This report allows the user to gain a deeper understanding of the ongoing events and trends in the needle free injection market. By correlating the historical data with key market dynamics, our analysts were able to make highly accurate projections in the report. MRFR’s report includes a thorough segmental analysis of the global needle free injection market segmented by product type, test type, end-user, and region with astute insights. This report has been prepared to assist industry participants in making informed decisions on growth strategies and operation management. Users will also come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the needle free injection market during the assessment period.
For the scope of research, the report offers a comprehensive analysis of the global needle free injection market.
Type of Medication
Site of Delivery
|CAGR||2020-2027: Substantial CAGR|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product, Technology, Usability, Type of Medication, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||CROSSJECT, Medical International Technology, Inc., National Medical Products Inc., INJEX Pharma GmBH, PenJet Corporation, Valeritas Holdings, Inc., Antares Pharma Inc., D'Antonio Consultants International, Inc., MIKA MEDICAL CO., PharmaJet, Inc., Endo Pharmaceuticals Inc., Inovio Pharmaceuticals Inc., and European Pharma Group|
|Key Market Opportunities||Prevalence of various chronic diseases|
|Key Market Drivers||Rise in investments in the pharmaceutical sector and convenient use of these medical devices in home care|
Frequently Asked Questions (FAQ) :
Needle free injections are syringes which deliver drugs through direct contact with the skin instead of a hypodermic needle. They can be used by children, adults, and patients with allergic conditions without any doctor supervision. It can prevent needle stick injuries, which is a common factor of disease transmission.
The needle free injection market expanding at an astounding CAGR of 15.8% during the forecast period (2018-2023).
The needle free injection market is anticipated to reach USD 25,057.4 million by 2023, as per a new detailed report by Market Research Future (MRFR).
The key players of the global needle free injection market include MIKA MEDICAL CO., PharmaJet, Inc., PenJet Corporation, Inovio Pharmaceuticals Inc., D'Antonio Consultants International, Inc., National Medical Products Inc., Valeritas Holdings, Inc., CROSSJECT, INJEX Pharma GmBH, Endo Pharmaceuticals Inc., Antares Pharma Inc., Medical International Technology, Inc., and European Pharma Group.
Prevalence of various chronic diseases is propelling the need for needle free injections. Rise in investments in the pharmaceutical sector and convenient use of these medical devices in home care is projected to drive market growth over the forecast period.
A large number of companies are present in the global needle-free injection market. The market players are continuously focusing on the increasing investments to produce novel products and increase their market reach. For instance, the company Antares Pharma received USD 2.75 million from Ferring Pharmaceuticals for its ZOMAJET needle-free auto-injector device. Moreover, it is reported that the U.S. Army Small Business Innovation Research (SBIR) program granted USD 500,000 to Inovio Pharmaceuticals for the development of needle-free delivery technology.
Some of the major market players profiled in the report are Antares Pharma Inc., Inovio Pharmaceuticals Inc., Endo Pharmaceuticals Inc., and Valeritas Holdings, Inc.
Antares Pharma, a U.S. pharmaceutical company, supplies, designs, and markets self-administered parenteral pharmaceutical products and technologies all over the world. The company has strategic alliances with AMAG Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. The company is focusing on alliances and collaborations to increase its cash flow and bolster sales. For instance, in October 2017, the company announced signing a definitive asset purchase agreement with Ferring Pharmaceuticals to sell the ZOMAJET needle-free auto-injector device for up to USD 14.5 million, thereby increasing its non-dilutive cash.
Inovio Pharmaceuticals Inc. is a worldwide developer, manufacturer, and marketer of pharmaceuticals against cancer and infectious diseases in the United States. The company has entered into an alliance with National Cancer Institute, Roche, MedImmune, Drexel University, University of Pennsylvania, National Institutes of Health (NIH), The Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, the U.S. Military HIV Research Program, and the University of Manitoba. The company is majorly focused on partnerships to develop advanced products. For instance, in January 2016, it received funding from government agencies for the development of needle-free electroporation delivery technology, thus changing the paradigm in vaccine administration.
Endo International plc., a pharmaceutical company produces and markets generic as well as branded pharmaceuticals in the United States and internationally. The company operates through three business segments, namely, the U.S. Generic Pharmaceuticals, International Pharmaceuticals, and the U.S. Branded Pharmaceuticals. The company is focused on expanding its generics and branded pharmaceuticals business by increasing research and development (R&D) investments and acquisitions. For instance, in April 2014, the company announced that it acquired rights from Zogenix, Inc. to sell Sumavel DosePro, a needle-free delivery system. This would fuel its branded pharmaceuticals business worldwide.
Other prominent players in the market include PharmaJet, Inc., Medical International Technology, Inc., INJEX Pharma GmBH, National Medical Products Inc., European Pharma Group, PenJet Corporation, CROSSJECT, MIKA MEDICAL CO., and D'Antonio Consultants International, Inc.